First AD

Second AD

Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Optimizing Therapy for Ovarian Cancer: Recent Data Highlights

Peer Exchange

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

PARP Inhibitor Resistance in Ovarian Cancer Treatment

Antibody-Drug Conjugates in Ovarian Cancer Treatment

Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

Investigative Therapies in Recurrent Ovarian Cancer

Treatment of Rare Tumors in Ovarian Cancer

Key Data Highlights in Ovarian Cancer